CUBE vs ENTA · P/E 25, rev $1.07B vs rev $65.3M
CubeSmart (CUBE) versus Enanta Pharmaceuticals Inc (ENTA) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Enanta Pharmaceuticals Inc (ENTA) is a biotechnology company listed on US.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported ENTA revenue for 2025-09-30 was $65.3M. Net income was -$81.9M. Revenue was down 3.4% from 2024-09-30 to 2025-09-30. ENTA currently screens at market cap $328.0M.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. ENTA currently screens at market cap $328.0M.
Not investment advice. Open the CUBE and ENTA stock pages for the full models.
Not investment advice.